To provide a method for predicting the response to the stimulation of agents by the use of genetic polymorphism and to provide markers used in the method for predicting the response to the stimulation of the agents.
The method includes the prediction of the response to Sorafenib of samples administered with Sorafenib by detecting in vitro genetic polymorphisms which decide the difference in the amount of expression of any one of the following (a)-(h) genes which show the difference between alleles in the amount of expression in response to the stimulation of Sorafenib: (a) dihydropyrimidine dehydrogenase gene, (b) CD247 molecule gene, (c) phospholipase A2, group IVA (cytosolic, calcium-dependent) gene, (d) interleukin 1 receptor, typeII gene, (e) dedicator of cytokinesis 2 gene, (f) estrogen receptor 1 gene, (g) complement component 5 gene, (h) phospholipase C, beta 1 (phosphoinositide-specific) gene, (i) pancreatic lipase-related protein 3 gene, and (j) lipase, hepatic gene.
ISHIKAWA SHUNPEI
IWAMOTO YASUNORI
YOSHIDA YASUHIKO
HIRAMATSU KONOSUKE
TSUJI SHINGO
Ishii Teiji
Satoshi Fujita
Natsuo Tanaka
Next Patent: COLLAGEN PEPTIDE-CONTAINING BEVERAGE